Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Abramson Cancer Center at Penn Medicine
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Pathologically confirmed adenocarcinoma of the pancreas.
Unresectable disease or borderline resectable disease assessed by a multidisciplinary panel of pancreas surgeon, medical and radiation oncologist, and a radiologist. Criteria defining unresectable and borderline resectable patients will be based on the NCCN Guidelines (v 1.2014):
Unresectable
Greater than 180 degrees of SMA encasement
Any celiac abutment
Unreconstructible SMV/portal occlusion
Aortic invasion or encasement
Nodal metastases beyond the field of resection Borderline resectable
Venous involvement of the SMV/portal vein demonstrating tumor abutment with impingement and narrowing of the lumen
Encasement of the SMV/portal vein but without encasement of the nearby arteries
Short-segment venous occlusion resulting from either tumor thrombus or encasement with suitable proximal and distal vessel for reconstruction/grafting.
Gastroduodenal artery encasement up to the hepatic artery with either short segment encasement or direct abutment of the hepatic artery, without extension to celiac axis
Tumor abutment to SMA but not to exceed greater than 180 degrees of circumferential vessel wall
Age \> 18 years.
ECOG performance status of ≤ 1.
Adequate organ function defined as follows: absolute neutrophil count of ≥ 1500/mm3, platelets ≥ 100,000/mm3, serum creatinine ≤ 2 mg/dl, total bilirubin ≤ 3, (with relief of biliary obstruction if present (PTC tube or endobiliary stent) and AST \< 5 times the upper limit of normal.
Patients of reproductive potential must agree to use an effective contraceptive method during participation in this trial and for 6 months after the trial.
Patients must be able to provide written informed consent.
You may not be if
Distant metastatic disease.
Prior history of abdominal radiation therapy.
Prior systemic therapy for pancreatic cancer.
Prior or simultaneous malignancy within the past 2 years (other than cutaneous squamous or basal cell carcinoma, melanoma in situ, thyroid carcinoma, or low-risk prostate cancer). In-situ carcinoma is allowed.
Serious uncontrolled concomitant systemic disorders or psychiatric condition that would interfere with the safe delivery of protocol therapy.
Treatment with an investigational anti-cancer agent within 4 weeks prior to enrollment into the study.
Pregnant women, women planning to become pregnant and women that are nursing
Clareo Health | A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer
